KISSEI PHARMACEUTICAL CO.,LTD. (4547) Stock Price

Kissei Pharmaceutical Co., Ltd. operates multiple business segments providing a diverse range of products and services.

1. **Pharmaceutical Business**

Kissei Pharmaceutical manufactures and sells prescription pharmaceuticals developed through its research and development efforts. The company also procures and sells prescription pharmaceuticals and healthcare foods (including foods for special dietary uses). Its non-consolidated subsidiary, KISSEI AMERICA, INC., collects and analyzes information on pharmaceutical development overseas and provides it to the company's research and development division.

2. **Merchandise Sales Business**

Consolidated subsidiary Kissei Shoji Co., Ltd. develops, produces, and sells noodle products, primarily Shinshu soba. The company also operates equipment and vehicle sales, fuel sales, and insurance agency services.

3. **Information Services Business**

Consolidated subsidiary Kissei Comtech Co., Ltd. provides system integration services, system resource services (including information equipment rental and network construction), and develops and sells medical systems. On January 1, 2025, the company absorbed and merged non-consolidated subsidiary Pros Co., Ltd.

4. **Construction and Facility Maintenance Business**

Consolidated subsidiary Hashiba Technos Co., Ltd. operates comprehensive construction services, ranging from building construction to equipment and facility maintenance and management.

Through these business segments, Kissei Pharmaceutical provides products and services that address diverse customer needs.

Kissei Pharmaceutical Co., Ltd. operates under the management philosophy of "Contributing to society on a larger scale through connection and harmony." The company prioritizes shareholders, employees, local communities, and the environment in its management approach. With pharmaceutical operations as its core business, the company focuses on developing and providing innovative medicines, with emphasis on research and development, manufacturing, and pharmaceutical information activities. Group companies support the pharmaceutical business and conduct operations both domestically and internationally.

The company will launch a new medium-term management plan called "Beyond 80" starting in 2025. This plan aims for sustainable growth as a drug discovery and development-focused company, with targets through fiscal year 2034 including expansion of the pharmaceutical business, enrichment of the research and development pipeline, establishment of new overseas revenue bases, and promotion of environmental management. The company targets ROE of 10% or higher and sales growth of 5% or higher.

As part of its growth strategy, the company has identified five priority areas. First, it will expand its research and development pipeline, focusing on small-molecule drug discovery utilizing AI technology. Second, it will pursue domestic business expansion through maximizing sales of existing products and commercializing new drugs. Third, it will expand overseas revenue by cooperating with partner companies to grow markets.

Additionally, the company will strengthen sustainability initiatives by advancing environmental management toward realizing a decarbonized, circular economy. In strengthening its management foundation, the company will promote digital transformation to improve operational efficiency and sophistication, while enhancing corporate governance. Through these strategies, Kissei Pharmaceutical aims to achieve sustainable growth.